Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).

scientific article published on 27 October 2016

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2016.09.025
P8608Fatcat IDrelease_dmctxmbpwjg4xl7qv2ooxwoele
P698PubMed publication ID28079022

P2093author name stringJodi Luchs
Edward J Holland
Aparna Raychaudhuri
Joseph Tauber
Kenneth Sall
Kelly K Nichols
Paul M Karpecki
Amir Shojaei
Monica Roy
Mitchell A Jackson
P433issue1
P921main subjectphase III clinical trialQ42824827
placebo-controlled trialQ108853737
placeboQ269829
eye diseaseQ3041498
P304page(s)53-60
P577publication date2016-10-27
P1433published inOphthalmologyQ7098109
P1476titleLifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
P478volume124

Reverse relations

cites work (P2860)
Q90615647A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain
Q92442286Advances in dry eye disease treatment
Q47639135Dry eye syndrome: developments and lifitegrast in perspective
Q36252489Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment
Q64916636Effects of packaging design on sensory liking and willingness to purchase: A study using novel chocolate packaging.
Q39069560Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease
Q38608475Lifitegrast for the treatment of dry eye disease in adults
Q33739879Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
Q93137705Lifitegrast: a novel drug for patients with dry eye disease
Q64106425Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
Q47739620Neuropathic pain and dry eye.
Q47268214Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
Q93341813Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo
Q49261503Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
Q90371647Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Q52608828Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye.
Q52661549Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products.
Q58694745Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
Q92236526Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
Q90351231The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options
Q48344821The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome.
Q47424328Update in Current Diagnostics and Therapeutics of Dry Eye Disease.
Q88350776n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease

Search more.